60 results about "Placenta" patented technology

The invention belongs to the technical field of aquatic product breeding, and particularly relates to a KASP molecular marker related to high temperature resistance character of patinopecten yessoensis and application of the KASP molecular marker in genetic breeding. On the basis of genome re-sequencing of 200 patinopecten yessoensis, a PySNP587919 locus obviously associated with the patinopecten yessoensis high-temperature-resistant character is screened by combining a whole genome SNP genotype and whole genome association analysis of the patinopecten yessoensis high-temperature-resistant character, and after the reliability of the locus is verified through Sanger sequencing, the locus is developed into a KASP marker, and the KASP marker can be used for identifying the high-temperature-resistant character of the patinopecten yessoensis and identifying the high-temperature-resistant character of the patinopecten yessoensis. The screening method can be used for screening the high-temperature-resistant comb shells. Furthermore, the invention also establishes a method for screening the high-temperature-resistant patinopecten yessoensis, and the method is efficient and accurate. Therefore, the technical scheme provided by the invention is suitable for molecular marker-assisted breeding work, rapid and effective screening of parents can be realized by typing the PySNP587919 site, and the breeding efficiency is improved.

This invention provides a traditional Chinese medicine composition for the prevention and treatment of knee arthritis. The active ingredients, by weight, include: 15-25 parts of Salvia miltiorrhiza, 8-15 parts of Ligusticum chuanxiong, 12-20 parts of Angelica sinensis, 7-15 parts of Lycopus lucidus, 15-30 parts of Poria cocos, 8-15 parts of Placenta hominis, 18-30 parts of Clematis chinensis, 15-25 parts of Spatholobus suberectus, 25-40 parts of Paeonia lactiflora, 12-20 parts of Rehmannia glutinosa, and 8-15 parts of Glycyrrhiza uralensis. Using Salvia miltiorrhiza, Ligusticum chuanxiong, Angelica sinensis, Lycopus lucidus, Poria cocos, Placenta hominis, Clematis chinensis, Spatholobus suberectus, Paeonia lactiflora, Rehmannia glutinosa, and Glycyrrhiza uralensis as raw materials, this invention follows the principle of "principal, assistant, adjuvant, and guide" in traditional Chinese medicine. The combined use of these herbs can tonify the liver and kidneys, promote blood circulation and remove blood stasis, and has a good therapeutic effect on knee arthritis caused by liver and kidney deficiency and qi stagnation and blood stasis.

The invention relates to the field of biological medicines, relates to a treatment technology for early abortion, and in particular relates to an application of Clostridium prausnitzii (Faecalibacterium prausnitzii) in preparation of a medicine for treating early abortion. An experiment of a Poly (I: C) induced early-stage abortion mouse model proves that the clostridium praeparatum can obviously reduce the embryo loss rate and improve placenta development through oral intragastric administration. The action mechanism is that maternal immune balance is regulated by increasing the proportion of regulatory T cells (Treg) and inhibiting excessive activation of an IL-17 signal channel. As human intestinal symbiotic bacteria, the clostridium praeparatum is high in safety and can be used for intervention of early abortion, especially recurrent abortion, and a new strategy is provided for clinic.

This invention belongs to the field of biotechnology and discloses a nucleic acid aptamer that specifically recognizes placental-specific protein 1 and its uses. The nucleotide sequence of the nucleic acid aptamer includes any one of the sequences shown in SEQ ID No. 1-57. This invention employs X-aptamer screening technology, combined with high-throughput sequencing technology and bioinformatics analysis, to reduce the number of screening rounds and obtain candidate nucleic acid aptamers. Further analysis of their affinity and specificity yields a nucleic acid aptamer that specifically recognizes placental-specific protein 1. The nucleic acid aptamer of this invention has the characteristics of high affinity and specificity, good stability, convenient synthesis, and easy labeling of functional groups. It can be used for the detection or binding of placental-specific protein 1, the diagnosis of placental-specific protein 1-related diseases, and the preparation of products for prognosis.

The present invention relates to the medical and food use of bile acid derivatives. Specifically, the present invention relates to the use of 3-oxoLCA in reducing oxidative stress and inflammation in pregnant mothers and their offspring. Specifically, the present invention relates to the use of 3-oxoLCA to reverse the effects of oxidative stress on pregnant mothers, in particular, to maintain fetal equal weight, significantly reduce placental and liver oxidative stress in pregnant mothers and the resulting inflammation or dysfunction of the placenta and liver, and to improve the intestinal flora imbalance of pregnant mothers. Further studies have found that 3-oxoLCA has long-term effects, in particular, can significantly reduce the effects of oxidative stress during pregnancy on oxidative stress and inflammation in the liver of offspring.

The present application relates to the field of traditional Chinese medicinal materials, in particular to a composition for resisting PRRSv and improving the reproductive performance of sows and application thereof. The present application formulates a composition composed of 10 plant extracts (Angelica sinensis extract, Atractylodes macrocephala Koidz extract, Glycyrrhiza uralensis Fisch extract, Eucommia ulmoides Oliver extract, Eucommia ulmoides leaf extract, Populus davidiana Dode extract, Perilla frutescens leaf extract, Gynostemma pentaphyllum Makino extract, Leonurus japonicus extract and Astragalus membranaceus Bge extract) for sows in late pregnancy, and collects sow blood and placenta samples at the time of delivery, studies the influence of the composition on sow reproduction, and explores the mechanism of action. The experimental results show that the composition can improve the reproductive performance of sows by increasing the total number of piglets and other indicators; meanwhile, the composition can effectively inhibit the replication of PRRSv.

This invention discloses a culture medium, preparation method, and culture method for the industrial-scale preparation of mesenchymal stem cells, belonging to the field of cell therapy technology. The culture medium comprises a basal medium, cell growth factors, cell proliferation promoters, a vitamin mixture, a nucleoside mixture, and an amino acid mixture; wherein the cell growth factors are selected from one or more of TGF-β, bFGF, VEGF, PDGF, EGF, and IGF. Through the synergistic effect of the composite nutrient system, this invention significantly improves the proliferation rate and cell viability of mesenchymal stem cells, maintains stem cell stemness, trilineage differentiation ability, and secretion levels of key cytokines (VEGF, HGF, TGF-β, IL-10, etc.); it can be stably and continuously passaged up to the 15th generation without abnormal changes in genetic material. This culture medium contains no animal-derived components, has high batch-to-batch stability, and is cost-controllable, making it suitable for GMP-level large-scale industrial preparation of mesenchymal stem cells from various sources such as umbilical cord, bone marrow, adipose tissue, and placenta.

This invention relates to the field of bioengineering technology, and in particular to a method for simultaneously collecting the inner cell mass and trophectoderm of mammalian blastocysts. The method includes the following steps: (1) after removing the zona pellucida of the blastocyst, the blastocyst is cut into an inner cell mass and a trophectoderm portion, and the cut trophectoderm portion is transferred to a culture medium for collection; (2) the inner cell mass portion obtained in step (1) is sequentially placed in an antibody treatment solution and a complement treatment solution for incubation; (3) the inner cell mass portion treated in step (2) is pipetted to obtain a purified inner cell mass. This method achieves simultaneous and efficient separation of two key cell lines from the blastocyst, fundamentally changing the traditional method's "resource waste" model of only obtaining the inner cell mass while discarding the trophectoderm, and providing more comprehensive experimental materials for embryonic development, placental biology, and stem cell research.

The invention relates to a method for constructing a preeclampsia prediction model by using clinical laboratory data and a related application thereof. Specifically, the preeclampsia risk prediction model is constructed based on a plurality of clinical indexes of pregnant women, a plurality of clinical laboratory data and insulin growth binding factor binding protein 1 and / or placental growth factors. The clinical laboratory data comprises leukocyte count and / or urine protein, and further comprises any one or combination of platelet count, monocyte proportion, glutamic-straw / glutamic-pyruvic transaminase ratio, glutamyltranspeptidase, uric acid and high-density lipoprotein. The constructed preeclampsia risk prediction model can provide a reliable implementation means for early prevention and early treatment of preeclampsia. Meanwhile, the sensitivity of the prediction model is 88.0% when the specificity of early eclampsia is 85.04% and the sensitivity of the prediction model is 62.5% when the specificity of late eclampsia is 85.04% in a complete independent verification set, and the detection performance of the prediction model is higher than that of the current detection performance.

The application provides a placenta perfusion and fetal development prediction method and system based on ultrasound images, and relates to the technical field of medical image analysis and diagnosis, which comprises the following steps: obtaining a placenta ultrasound image and pre-processing and quality control; segmenting the placenta region through a deep neural network, extracting multi-dimensional features of gray scale, texture, shape and blood flow; inputting a machine learning model to predict the perfusion and fetal development state; visualizing the results and key factors, combining clinical verification and generating intervention suggestions. The system comprises image processing, segmentation, prediction, visualization and verification interpretation modules. The application realizes objective quantitative evaluation, solves AI problems, forms full-chain clinical support, improves early warning accuracy, helps precise intervention and reduces perinatal risks.

The invention discloses hydrogel based on umbilical cord tissue and chorion tissue, which is prepared by a method comprising the following steps: (1) taking a placenta, shearing the umbilical cord and separating the chorion; (2) respectively carrying out tissue crushing on the umbilical cord and the chorion, and centrifugally collecting precipitates; mixing, washing, centrifuging and collecting precipitates; (3) freezing with liquid nitrogen, and then melting; repeatedly freezing and thawing; adding a buffer solution containing triton-X-100, and carrying out soaking treatment; rinsing, centrifuging and collecting precipitates; (4) adding urea, oscillating, centrifuging and collecting precipitate; freezing and drying to obtain freeze-dried powder; (5) dissolving the freeze-dried powder in hydrochloric acid, adding pepsin, and reacting; and adjusting the pH value to 7-7.5 to obtain the hydrogel. The hydrogel is applied to culture of cells, tissues or organoids, and is applied to preparation of a culture medium with the effect of promoting angiogenesis. The method is of great significance to development in the fields of regenerative medicine, disease modeling, medicine development and the like.

The present invention provides decidual placental mesenchymal stem cells and a method for culturing the same, which comprises introducing an induction step into a conventional method for culturing mesenchymal stem cells to highly express decoy receptor 3 (DcR3) in the decidual placental mesenchymal stem cells.Furthermore, the present invention provides a use of the decidual placental mesenchymal stem cells in the manufacture of a drug for promoting angiogenesis.

The invention provides methods for prognosing an increased risk of early onset preeclampsia (EOPE) in a pregnant subject before the disease onset. The methods comprises quantifying small extracellular vesicles that express pairs of biomarkers selected from CD10, CD63 and placental alkaline phosphatase (PLAP) in a sample obtained from the subject.

The application relates to circular RNA diagnostic markers for placenta implantation lineage diagnosis and application thereof. The circular RNA diagnostic markers comprise one or two of circPHACTR4 and circZMYM4, and the cDNA sequences of the circPHACTR4 and the circZMYM4 are respectively shown as SEQ ID NO: 1 and SEQ ID NO: 2. The two circular RNA diagnostic markers are significantly up-regulated in PAS peripheral blood, and can be used as PAS diagnostic markers alone or in combination to realize high-sensitivity, specificity and objective detection of placenta implantation lineage. The sensitivity of circPHACTR4 alone is 74%, the sensitivity of circZMYM4 alone is 68.4%, the two circRNAs are combined to have a good prediction effect on PAS, and the sensitivity and specificity can reach 82% and 88.9% in combination with the diagnosis results of clinical indexes and B ultrasonic waves, so that the precision of the prenatal diagnosis of PAS is greatly improved.

The invention provides a primer probe group for noninvasive detection of gene polymorphism of a placenta drug transporter. The primer probe group comprises a primer probe group for detecting c.80G > A polymorphism of an RFC1 gene or / and c.1236Cgt of an ABCB1 gene, a primer probe set of T polymorphism; the method for noninvasive detection of placenta drug transporter gene polymorphism comprises the following steps: taking peripheral blood free DNA (deoxyribonucleic acid) of a pregnant woman in a gestation period as a template, and performing micro-droplet generation and PCR (polymerase chain reaction) amplification by using a primer probe group to obtain an RFC1 gene c.80Ggt; a or / and an ABCB1 gene c.1236Cgt; and carrying out genotype analysis on copy number information of T mutation sites. The invention further provides application of the primer probe set for noninvasive detection of placenta drug transporter gene polymorphism, and the primer probe set is used for preparing a kit for noninvasive detection of placenta drug transporter gene mutation site genotypes. According to the invention, the peripheral blood DNA of the pregnant woman in the gestation period is detected by using digital PCR, the placenta drug transporter gene mutation information is noninvasively obtained, the transplacental transport of the drug and the possible influence on the fetus are evaluated, and an important reference is provided for the treatment decision of the pregnancy complication / complication and the like.

The invention discloses a fetal growth restriction diagnostic reagent and method based on METTL1 regulation and control of SLC7A11 m7G modification. The diagnostic reagent comprises a reagent for specifically detecting the expression level of an METTL1 gene and a reagent for detecting the m7G modification level of the SLC7A11 gene. The diagnosis method comprises the following steps: collecting a placenta tissue sample of a pregnant woman, respectively detecting the m7G modification level of an SLC7A11 gene and the expression level of an METTL1 gene by utilizing a MeRIP-seq technology and a real-time fluorescent quantitative PCR technology, and realizing the diagnosis on the fetal growth limitation by combining the detection results of the m7G modification level and the expression level. By researching the m7G modification regulation mechanism of METTL1 to SLC7A11, a novel diagnostic marker and a novel diagnostic method are provided for fetal growth limitation, and the marker has the advantages of high specificity, high sensitivity, accurate result and the like, and can be widely applied to early diagnosis of clinical fetal growth limitation.

This application discloses a deer placenta drying device for preparing deer placenta cream, belonging to the technical field of deer placenta drying devices. It includes a drying chamber with a control cabinet fixedly mounted on its upper surface. The control cabinet houses an electric heating device and a hot air blower. Multiple tray assemblies rotatably mounted on a storage rack allow for easy loading and unloading of deer placenta, facilitating use and operation. Electric heating tube assemblies are installed on both inner walls of the drying chamber, creating a counter-heating function. A series hot air channel is formed between the hot air blower and the drying chamber via two Z-shaped air ducts, ensuring stable temperature inside the chamber while maintaining good air circulation. This provides excellent permeability, allowing the deer placenta to fully contact the air as the tray assemblies rotate, accelerating moisture evaporation and achieving efficient and uniform drying. This significantly shortens drying time and improves production efficiency.

Compositions comprising perforated, unseparated amnion / chorion; perforated, separated amnion; and perforated, separated chorion derived from the placenta and methods of preparing and using those compositions are provided. Perforation of placental tissue before or during processing may allow for one or more benefits such as more efficient removal of blood remnants, retention of wound healing and tissue regeneration components, better handling characteristics, or improved healing capacity. The present invention also includes methods of healing a wound of the skin, eye, nerve, tendon, or dura comprising applying the perforated compositions of the invention to the wound.

Artificial womb (10) for the care of a premature infant (F) in particular until its lungs are mature or it is ready for birth, with - a reservoir (120) with a wall (121) for receiving the premature infant (F) and amniotic fluid (W); - an artificial placenta (150) with a connector (152) for connecting the umbilical cord (N) of the premature infant (F), wherein the artificial placenta (150) comprises at least one membrane (151) through which oxygen from the ambient air of the artificial womb (10) or from an oxygen reservoir (155) is supplied to the artificial placenta (150) for oxygenating the blood of the premature infant (F); and - a housing (110) in which the reservoir (120) and the artificial placenta (150) are arranged, wherein the housing (110) in particular has a compact shape, wherein the artificial uterus (10) is portable.

Disclosed is a method for assessing the age of a tissue, in particular the placenta, using circular RNAs. Further disclosed are methods for diagnosing or predicting the risk of a pregnancy complication, such as stillbirth, by quantifying circular RNAs in the placenta or a maternal blood sample.

1. The name of the designed product: packing box (deer fetus cream). 2. The use of the designed product: for packing box. 3. The design points of the designed product: the combination of shape, pattern and color. 4. The picture or photo that best shows the design points: perspective view. 5. The design contains colors.

The invention relates to an amniotic fluid cell culture medium and a preparation method thereof, and belongs to the technical field of cell culture mediums. The culture medium comprises a basic culture medium, a fermented animal polypeptide compound and auxiliary components, the fermented animal polypeptide compound is formed by compounding fermented bovine bone collagen peptide and fermented sheep placenta peptide according to a specific proportion, and polypeptide is subjected to bacillus subtilis fermentation, enzymolysis and purification and then passes through a 0.22 mu m polyether sulfone filter membrane terminal for sterilization. By utilizing the synergistic effect of the fermented animal polypeptide, the proliferation rate and metabolic activity of the amniotic fluid cells are effectively improved, meanwhile, stable physical and chemical properties, standard sterility, definite components, small batch difference and no need of adding fetal calf serum and plant-derived components are ensured, and the method is suitable for amniotic fluid cell culture in prenatal diagnosis.

This invention discloses a system for early screening of neurodevelopmental delay in mid-to-late-term preterm infants. Based on the expression levels of two mRNAs, APOE and CST3, in the placenta, this invention establishes a "2-mRNA Panel" classification model for early screening of neurodevelopmental delay in mid-to-late-term preterm infants. The area under the receiver operating characteristic curve (AUC) for gross motor delay, fine motor delay, and personal-social functional delay reaches 86.1%, 82.2%, and 83.3%, respectively. Therefore, APOE and CST3 mRNAs in the placenta can serve as biomarkers for neurodevelopmental delay in mid-to-late-term preterm infants, providing a valuable supplement to the development of early screening tools for neurodevelopmental delay. This invention has significant application value.

The invention relates to a composition containing stem cells and application of the composition in ovarian aging resistance. According to the invention, the polypeptide TP-TOF with ovarian aging resistance is separated and screened from placenta, and the polypeptide can effectively reduce apoptosis of ovarian granular cells. The polypeptide can effectively promote recovery of ovarian estradiol and follicular poietin levels of rats independently or in combination with stem cells, can remarkably prolong the estrus period, reduce the estrus interval, reduce follicle apoptosis and promote follicle generation, and has a wider application prospect.

13-cis retinoic acid (13-cis) is a potent teratogen that crosses the placenta and exists in equilibrium with 13-trans retinoic acid (13-trans). Compared to 13-trans, 13-cis is preferentially concentrated in the cell nucleus where it is isomerized to teratogenic 13-trans. In pregnant mothers the plasma 13-cis concentration is highest in the first 8-12 weeks of pregnancy. Neurocognitive impairment even in the absence of any physical defects has been reported to be 30%-60% of children exposed to Isotretinoin (13-cis) during the prenatal period. Genetic variability of CYP26A1 and / or CYP26B1 may be passed onto the fetus and is probably associated with increased maternal and fetal retinoid concentrations. Beta carotene crosses the placenta but may be metabolized and / or stored by the fetus differently than in adults. Measuring maternal retinoids and CYP26A1 and CYP26B1 activities may provide insight into the steep rise in neurodevelopment disorders not explained by improvement in diagnosis.

The present technology provides antibodies, antigen binding fragments and antibody-drug conjugates (ADC) specific for placental alkaline phosphatase (ALPP) and / or placental-like alkaline phosphatase 2 (ALPPL2), which are useful as potential therapeutic agents for the treatment of diseases, including cancer.

A method for constructing a preeclampsia prediction model by using clinical laboratory data and the use thereof. Specifically, the preeclampsia risk prediction model is constructed on the basis of several clinical indexes of pregnant women, several pieces of clinical laboratory data, and insulin-like growth factor-binding protein 1 and / or placental growth factor. The several pieces of clinical laboratory data comprise white blood cell count and / or urine protein, and further comprise any one or a combination of platelet count, monocyte percentage, aspartate aminotransferase / alanine aminotransferase ratio, glutamyl transpeptidase, uric acid and high-density lipoprotein. The constructed preeclampsia risk prediction model can provide a reliable implementation means for early prevention and early treatment of preeclampsia. Moreover, in a fully independent validation set, when the specificity of the prediction model for early-onset preeclampsia is 85.04%, the sensitivity is 88.0%, and when the specificity for late-onset preeclampsia is 85.04%, the sensitivity is 62.5%, outperforming the current detection performance.

The application belongs to the technical field of medicine preparation, and particularly relates to application of cellulose nanofiber in preparation of medicine for preventing or treating gestational diabetes mellitus. In the application, the CNF has significant adsorption capacity for micro / nano plastic due to its high specific surface area and unique surface characteristics. Moreover, the CNF intervention can effectively reduce the deposition of microplastics in organs such as liver and placenta, and reduce the trans-barrier transport and biological toxicity of harmful particles from the source. In addition, the CNF can effectively repair the intestinal barrier damage caused by microplastic exposure or high-fat diet, and reduce the systemic inflammation level. Furthermore, the CNF intervention can significantly reduce the fasting blood glucose of the microplastic exposure model mouse during pregnancy, improve the area under the curve (AUC) of insulin tolerance test (ITT) and oral glucose tolerance test (OGTT), and restore the insulin sensitivity.

The invention relates to an anti-aging, wrinkle-fading, brightening and skin-care formula and a preparation method. The formula comprises a core active component, an auxiliary active component, a moisturizing additive, a soothing and repairing agent, a preservative, a water-phase basic auxiliary material and deionized water, the core active component contains modified sheep placenta small molecular protein, acetyl hexapeptide-8 and glutathione; the preparation method comprises the steps of water-phase matrix preparation, primary mixing, active component adding and dispersing, pH adjusting, curing and the like, and sheep placenta micromolecular protein is subjected to pretreatment, enzymolysis and performance modification and optimization. The formula components are scientifically compounded, the preparation process is accurate, and the product stability and mildness are excellent; the composition can effectively increase the collagen content of the skin, reduce fine wrinkles and brighten the skin color, has good moisturizing and preservative effects, and has a use effect superior to that of a conventional skin care formula.